Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

Hims teamed up with Novo Nordisk A/S in April to offer its rival drug Wegovy at a discounted price to patients who use its platform. The telehealth company — and its investors — had been ...

Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk's Wegovy.

Zepbound joins the GLP-1 ranks for weight loss with Wegovy and Saxenda. Tirzepatide is the main ingredient in Zepbound, approved label for weight management, and Mounjaro, the brand name approved ...

In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.

Zepbound growth has outpaced Wegovy in recent months, and sales quadrupled to $2.31 billion in the first three months of this year compared to the same period of 2024, while Mounjaro more than ...

Shares of Scholar Rock jumped 16% in premarket trading. Scholar's drug, apitegromab, when combined with Zepbound preserved an additional 1.9 kilograms of lean mass when compared with Zepbound alone.

(Reuters) -Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday. With ...

The compounded versions cost consumers considerably less than the brand-name GLP-1 drugs. Novo Nordisk said it had been working with telehealth companies to help transition patients from the ...